| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 33MM | -7% |
| Gross Profit | 23.3MM | - |
| Cost Of Revenue | 9.7MM | +38% |
| Operating Income | -32.3MM | -86% |
| Operating Expenses | 55.6MM | - |
| Net Income | -57.4MM | -79% |
| G&A | 24MM | +14% |
| Amortization | 4.8MM | -53% |
| Interest Expense | - | - |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
LAKE FOREST, Ill., April 25, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that it will release first quarter 2024 financial results on Monday, May 6, 2024, after the market close. Following the release of its financial results, Assertio’s management will host a live webcast of the earnings conference call at 4:30 p.m.
LAKE FOREST, Ill., April 03, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced effectiveness of the appointment of Sigurd (Sig) Kirk to its board of directors. He will serve on the Audit and Compensation committees. Kirk is a senior corporate business development executive with more than 20 years of pharmaceutical experienc
LAKE FOREST, Ill., April 01, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that Ajay Patel, Chief Financial Officer, will present at the LD Micro Invitational XIV Conference to be held April 9, 2024 in New York City. The Company will host a group presentation at 4:00 pm Eastern Time, and be available for individual meet
Today is shaping up negative for Assertio Holdings, Inc. ( NASDAQ:ASRT ) shareholders, with the analysts delivering a...
Net Sales Dip but Cash Flow Remains Positive; Company Sets 2024 Guidance for Growth
Assertio Holdings, Inc. (NASDAQ:ASRT) Q4 2023 Earnings Call Transcript March 11, 2024 Assertio Holdings, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank you for standing by, and welcome to the Assertio Holdings Fourth Quarter and Full Year 2023 […]
Q4 2023 Assertio Holdings Inc Earnings Call
Fourth Quarter Net Product Sales $32.5 Million, Cash Flow from Operations of $5.7 Million 2024 Full Year Outlook for Net Product Sales of $110 to $125 Million, Adjusted EBITDA of $20 to $30 Million LAKE FOREST, Il., March 11, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today reported financial results for the fourth quarter and full
LAKE FOREST, Ill., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company that acquires, commercializes and develops safe and effective therapies that make a difference in the lives of patients, today announced that it will release fourth quarter and full year 2023 financial results on Monday, March 11, 2024, after the market close. Following the release of its financial results, Assertio’s management will host a
Assertio (ASRT) appears weighed down by the recent leadership transition. The company is also facing challenges with sales of its product franchisee of late.